Browning of White Fat: Novel Insight Into Factors, Mechanisms, and Therapeutics

NEVENA JEREMIC, PANKAJ CHATURVEDI, AND SURESH C. TYAGI*

Department of Physiology, University of Louisville, Louisville, Kentucky

What is more interesting about brown adipose tissue (BAT) is its ability to provide thermogenesis, protection against obesity by clearing triglycerides, releasing batokines, and mitigating insulin resistance. White adipose tissue (WAT) on the other hand stores excess energy and secretes some endocrine factors like leptin for regulating satiety. For the last decade there has been an increasing interest in the browning of fat keeping in view its beneficial effects on metabolic disorders and protection in the form of perivascular fat. Obesity is one such metabolic disorder that leads to significant morbidity and mortality from obesity-related disorders such as type 2 diabetes mellitus (T2D) and cardiovascular disease risk. Browning of white fat paves the way to restrict obesity and obesity related disorders. Although exercise has been the most common factor for fat browning; however, there are other factors that involve: (1) beta aminoisobutyric acid (BAIBA); (2) gamma amino butyric acid (GABA); (3) PPARγ agonists; (4) JAK inhibition; and (5) IRISIN. In this review, we propose two novel factors musclin and TFAM for fat browning. Musclin a myokine released from muscles during exercise activates PPARγ. Various factors involved in fat browning are mentioned below:

- Musclin: A myokine released from muscles during exercise activates PPARγ and secretes some endocrine factors like leptin for regulating satiety. For the last decade there has been an increasing interest in the browning of fat keeping in view its beneficial effects on metabolic disorders and protection in the form of perivascular fat. Obesity is one such metabolic disorder that leads to significant morbidity and mortality from obesity-related disorders such as type 2 diabetes mellitus (T2D) and cardiovascular disease risk. Browning of white fat paves the way to restrict obesity and obesity related disorders.

- TFAM: A transcription factor that induces mitochondrial biogenesis.

Since BAT is rich in mitochondria, higher expression of TFAM in WAT or TFAM treatment in WAT cells can induce browning of WAT. We propose that fat browning can be used as a therapeutic tool for metabolic disorders and cardiovascular diseases.

Brown adipose tissue (BAT) is specialized in energy expenditure and it is present in nearly all mammalian species (Giralt and Villarroya, 2013; Nedergaard and Cannon, 2014). BAT has an important thermogenic function as a natural defense system against cold stress in newborn mammals and in adults. BAT has not only crucial role against hypothermia but also has a power to modulate the proton gradient by uncoupling cellular respiration from mitochondrial ATP synthesis. After many years of research, studies have shown that the expression of uncoupling protein 1 (UCP1) in response to cold stress, or food intake resulting in regulation of energy balance (increased glucose and free fatty acid oxidation) leads to the generation of heat and serves to protect an organism from hypothermia (Algire et al., 2013; Roman et al., 2015; Sidossis and Kajimura, 2015). BAT is characterized by small lipid droplets (LDs) and microstructurally high number of mitochondria (Kiefer et al., 2012; Rezaee, 2013). Storage of energy in the form of triglycerides (TGs) in LDs is accessible for rapid hydrolysis and oxidation of fatty acids (FAs) (Rezaee, 2013; Warner and Mittag, 2016). BAT is derived from precursor cells, which share the same lineage as skeletal muscle cells and are positive for Myf5 (Zafrir, 2013; Giralt and Villarroya, 2016). Contrary to the skeletal muscle cells, BAT progenitors initiate the expression of PRDM16 and BMP7 during development, which drives them to become mature brown adipocytes (Ohno et al., 2012; Zafrir, 2013). BAT is present in adult humans and its beneficial properties like inverse correlation with body mass index (BMI), high vascularity to enhance the transfer of the thermogenic effect throughout the body, results in metabolism of enough TGs to have an impact on overall body weight, and metabolic

population without insulin resistance. Though the mechanism is unclear, but it is speculated to be mediated by the inhibition of hepatic glucose output and amelioration of glucose uptake in the muscle which leads to increasing fatty acid oxidation and higher energy consumption in vitro, probably by increased uncoupling of adenosine triphosphate (ATP) generation in mitochondria (Berg et al., 2001; Fruebis et al., 2001; Hajer et al., 2008). Other endocrine factors that are secreted by adipose tissues include fibroblast growth factor 21 (Liu et al., 2013a), interleukin 6 (Fontes et al., 2015), free fatty acids (Yore et al., 2014), and nerve growth factors (Zheng et al., 2015) (Fig. 3) which are beneficial and cardioprotective. One of the important roles of the BAT is to provide non-shivering thermogenesis by uncoupling the electron transport chain from ATP synthesis using uncoupling protein 1 (UCP1) (Seale and Lazar, 2009). BAT is present as perivascular fat which secretes vasorelaxing/vasoconstriction factors and maintains vascular tone (Xu et al., 2010). Keeping in view the beneficial effects of BAT, the factors that mediate browning of fat are of immense importance. These factors include beta-amino isobutyric acid (BAIBA), gamma amino butyric acid (GABA), PPAR γ, exercise, IRISIN and micorRNAs (Fig. 2). This review summarizes the current knowledge about BAT, browning of WAT, and factors that underline the conversion of WAT to BAT, as well as their use as therapeutics for metabolic diseases such obesity and T2D.

White and Brown Adipose Tissue

Modern life style that includes most time during the day in seated position, with consumption of calorie-dense food and with little or totally without physical activity is a very big step closer to obesity. This condition poses a severe threat to worldwide public health. Also, it is particularly alarming because of the pathological accumulation of excess dysfunctional adipose tissue that characterizes obesity and it is a major risk factor for many other diseases, including T2D, heart disease, insulin resistance, hyperglycemia, dyslipidemia, hypertension, and some types of cancer (Seale and Lazar, 2009; Harms and Seale, 2013; Reddy et al., 2014). The major role of WAT according to classical view of its function is providing a long term metabolic fuel which is especially convenient when there are long periods of some physical efforts. In times of caloric need, during fasting or absence of energy intake, storage of triglycerides (TGs), and releasing of fatty acids (FAs) for oxidation will be a key in maintaining of energy balance in organism (Trayhurn and Beattie, 2001; Yazquez-Vela et al., 2008; Wang et al., 2008). WAT has two depots in body: visceral white adipose tissue (vWAT) and subcutaneous white adipose tissue (scWAT) (Stanford et al., 2015). Both type of WAT are very much involved in functions such as: lipid storage, hormone production, immune function, and local tissue architecture. However, development of type 2 diabetes mellitus (T2DM) and cardiovascular complications is more connected with increased amount of vWAT (Roman et al., 2013; Stanford et al., 2015) while accumulation of scWAT is associated with improved insulin sensitivity and a reduced risk for developing T2DM (Stanford et al., 2015).

Brown adipose tissue (BAT) is specialized in energy expenditure and it is present in nearly all mammalian species (Giralt and Villarroya, 2013; Nedergaard and Cannon, 2014). BAT has an important thermogenic function as a natural defense system against cold stress in newborn mammals and in adults. BAT has not only crucial role against hypothermia but also has a power to modulate the proton gradient by uncoupling cellular respiration from mitochondrial ATP synthesis. After many years of research, studies have shown that the expression of uncoupling protein 1 (UCP1) in response to cold stress, or food intake resulting in regulation of energy balance (increased glucose and free fatty acid oxidation) leads to the generation of heat and serves to protect an organism from hypothermia (Algire et al., 2013; Roman et al., 2015; Sidossis and Kajimura, 2015). BAT is characterized by small lipid droplets (LDs) and microstructurally high number of mitochondria (Kiefer et al., 2012; Rezaee, 2013). Storage of energy in the form of triglycerides (TGs) in LDs is accessible for rapid hydrolysis and oxidation of fatty acids (FAs) (Rezaee, 2013; Warner and Mittag, 2016). BAT is derived from precursor cells, which share the same lineage as skeletal muscle cells and are positive for Myf5 (Zafrir, 2013; Giralt and Villarroya, 2016). Contrary to the skeletal muscle cells, BAT progenitors initiate the expression of PRDM16 and BMP7 during development, which drives them to become mature brown adipocytes (Ohno et al., 2012; Zafrir, 2013). BAT is present in adult humans and its beneficial properties like inverse correlation with body mass index (BMI), high vascularity to enhance the transfer of the thermogenic effect throughout the body, results in metabolism of enough TGs to have an impact on overall body weight, and metabolic
health (Reddy et al., 2014; Roman et al., 2015; Tharp and Stahl, 2015).

BAT cells possess large number of mitochondria that contain a unique protein called uncoupling protein 1 (UCP1) which is a very important regulatory factor in the thermogenesis (Seale and Lazar, 2009). Cold sensations signal neurons up to the preoptic area of the hypothalamus, further activating the sympathetic nervous system to release norepinephrine, which induces UCP1 and BAT activity (Kiefer et al., 2012; Zafrir, 2013). The benefits of UCP1-expressing BAT may not be limited to their metabolic characteristics, but also their property as a potent secretome (Tharp and Stahl, 2015). It is

Fig. 2. A comprehensive view of the factors involved in the process of browning. Exercise has beneficial effects on browning but many other factors are also promoted according to physical activity such as (1) beta aminoisobutyric acid (BAIBA); (2) gamma aminobutyric acid (GABA); (3) IRISIN; (4) fibroblast growth factor 21 (FGF21); and (5) musclin (PPARγ agonist). Beside all these factors cold exposure can lead to browning through UCP1. The possible mechanisms involve lipogenic pathways.

Fig. 3. Cardioprotection through browning of fat. Browning of fat can lead to cardioprotection in three ways: (1) by secreting batokines like FGF21, adiponectin, nerve growth factors, and free fatty acids; (2) by maintaining vascular tone through secretion of vasorelaxing/vasoconstricting factors from perivascular and epicardial tissues; and (3) by reducing the levels of triglycerides and mitigating insulin resistance and limiting cardiac injury.
well known that WAT and BAT do not have the same precursor cells and that they share the same origin as skeletal muscle cells (Kiefer et al., 2012; Roman et al., 2015). In spite of the fact that classical BAT shares precursors with skeletal muscles and is present in interscapular areas, perirenal, and periaortic regions, we have beige (bright) tissue—BAT, that is, present mainly in WAT itself (Koppen and Kalkhoven, 2010; Kiefer et al., 2012; Roman et al., 2015). The evidence of existence of BAT in WAT reveals the real meaning of term "browning". In addition, accumulation of both vWAT and scWAT lead to the development of T2D and obesity that subsequently lead to cardiovascular complications (Cypess et al., 2009; Cypess and Kahn, 2010). However, existence of BAT is beneficial and its role in animals as well as in humans much needs to be explored.

**Role of WAT and BAT in Metabolic Disorders**

The treatment of patients with metabolic disorders requires significant efforts on the first place in lifestyle modifications, which are often difficult to apply and they are only partially successful. Consequently, during the years a lot of time, money, and exertion were spent to find a potential therapeutic target to treat obesity and associated diseases (Zafrir, 2013; Warner and Mittag, 2016). However, today, some studies suggest that the solution might be adipose tissue (AT) itself. AT has been reported as the main energy reservoir organ in the body. Although insulin regulates metabolism in both brown and white adipocytes, the role of these tissues in energy storage and utilization is quite different. Moreover, today significant number of studies are showing how and in which manner especially BAT plays role in obesity and T2D. Despite a similar ability to undergo thermogenesis, brown and beige cells have many different characteristics and should be considered as distinct cell types for several reasons as described by Harms and Seale (2013). However, in both brown and beige adipocytes, very similar amounts of UCP1 were found after activation which indicates same thermogenic capacity which shows that they have more than one similar function (Harms and Seale, 2013). UCP1, when activated, uncouples electrons transport in the respiratory chain from generation of adenosine triphosphate (ATP) and thus releases the energy stored in the form of heat (Zafrir, 2013). Thus, it is now understandable that cold exposure of overweight patients can lead to better activation of BAT, but could also corroborate the inverse association with BMI. Finally, studies showed that BAT prevalence and activity were much lower in patients with severe obesity, and BAT activity was increased in this group after weight loss induced by bariatric surgery (Betz and Enerback, 2015). Although the idea of stimulating BAT activity in way of cold exposure to combat obesity is interesting approach, we should be realistic and see if it is also comfortable for patients. One study actually indicates that cold acclimation for 10 days (14–15°C) leads to increased peripheral insulin sensitivity by ~43% in eight subjects with T2D (Hanssen et al., 2015).

A recent study on mice shows that browning of WAT via cold exposure can greatly improve the anti-diabetic effect of T0901317 (potential agonist of liver X receptors) in diabetic mice. The results from this study suggested that browning of WAT via cold exposure or molecules such as fibroblast growth factor 21 (FGF21), IRISIN, and Nrg4 would be an excellent strategy in managing insulin-dependent diabetes (Gao et al., 2015). Similarly, another group of investigators showed important role of FGF21 in the process of browning. They showed clear function for FGF21 in regulating chronic adaptive thermogenesis by increasing the transcription of thermogenic genes and enhancing the thermogenic capacity of the organism by "browning" white fat (Fisher et al., 2012). In last century, scientist tried to mimic the effect of activated UCP1 using chemical uncoupler 2, 4-dinitrophenol (DNP) substance. However, when it is applied in high doses, it can cause irregularity of respiratory uncoupling in all cells causing dangerous side effects, including hyperthermia and death (Harms and Seale, 2013). Hence, there was an urge to investigate new factors that mediate browning of fat without having any side effects.

**Factors Which Underline Browning**

Since the end of the 20th century researchers are trying to define the process of browning. The important landmark in this field of research was studies on animals as well as on humans exposed to cold conditions. In these types of studies, it was obvious that BAT activity in man was acutely cold induced and was stimulated via the sympathetic nervous system (Huttunen et al., 1981; Nedergaard et al., 2007; Nedergaard and Cannon, 2014). Taking all that in consideration, recent studies on mice have reported that browning can be mediated by the emergence of UCP1-expressing cells in WAT not only by cold exposure or adrenergic stimulation but also by hormonal stimuli (Lo and Sun, 2013; Moisan et al., 2015). According to these mediators we now know few regulatory pathways of browning such as PGC-1α, C/EBPs, PPARγ (peroxisome proliferator-activated receptor gamma), PRDM16, SRC-1 (steroid receptor coactivator-1) and TIF2 (transcriptional intermediary factor-2), TBX15 (T-box 15), and TFAM (mitochondrial transcription factor A). Other transcription factors and coregulators include FoxC2 (forkhead box protein C2), IRISIN (secreted protein), BMP7 (bone morphogenetic protein 7), FGF21, 4E-BP1 [eIF4E (eukaryotic translation initiation factor 4E)-binding protein 1], CNP (cardiac natriuretic peptide), TRPV4 (transient receptor potential vanilloid 4), COX (cyclo-oxygenase)-2, and miRNAs (microRNAs) (Fig. 2) (Lo and Sun, 2013).

**PPARγ**

PPARγ has a key and irreplaceable role in the regulation of differentiation of both WAT and BAT though they have similar transcription pathways (Koppen and Kalkhoven, 2010; Lo and Sun, 2013). The importance of PPARγ is evident from clinical implications of its agonists which lead to increased expression of adiponectins especially in therapy of insulin resistance and T2D (Koppen and Kalkhoven, 2010). Studies also show that patients with a dominant-negative mutation in the PPAR-γ gene have very serious diabetic condition which indicates a correlation between T2D and this signaling molecule (Barroso et al., 1999). According to these findings we can assume a very important impact of this factor on the process of browning in clinical cases such as T2D. Moreover, Ohno et al. (2012) in their study, showed that full PPARγ agonists, such as rosiglitazone, bind to and stabilize helix12 of the ligand binding domain (LBD) of PPARγ which leads to extended accumulation of PRDM16. PRDM16 has a pivotal role in the development of beige cells in subcutaneous WAT. Partial agonist of thiazolidinedione (TZD) such as non-TZD compounds (MRL24, nTZDpa) predominantly show effects on helix3 and the β-sheet region, with minimum influence on helix12 and based on this they have a very weak or no browning effect at all (Ohno et al., 2012). In present, browning and the search for beige progenitors in human WAT has become a burning issue for the scientific world.

**MicroRNAs**

MicroRNAs which are small ~18–25 nucleotide entities, are interesting candidates affecting browning of fat. Zheng et al., in their investigations showed important role of microRNAs
(miRNAs) in the process of WAT browning especially epididymal adipose tissue. Their findings suggest a potential UCP1-targeting miR-9 and miR-338-3p to be involved in the process of browning of epididymal adipose tissue through posttranscriptional suppression of UCP1 gene expression (Zheng et al., 2014). Liu et al. showed that miR-133a inhibits white adipocyte browning and negatively regulates PRDM16. According to this, they found that miR-133a KO mice have dramatic phenotypes including adipocyte browning, improved glucose metabolism, and insulin sensitivity (Liu et al., 2013b). Also, another group of authors suggested that miR-34a may provide an effective therapeutic option for combating obesity-related metabolic disorders, especially because of the effects of anti-miR-34a on increased expression of UCP1 in all types of adipose tissues. This is due to the fact that downregulation of miR-34a also impairs hepatic FGF21 signaling and lipid oxidation (Fu et al., 2014). One of the possible targets in treatment of obesity and T2D could be miR-155 though it is in the initial stage of research. Studies conducted on mice suggest that reduction of miR-155 for 50% already enhances recruitment of beige fat cells and differentiation of BAT. According to this, therapeutic strategies to reduce miR-155 might be a promising strategy in treatment of metabolic disorders (Chen et al., 2013). Finally, as miRNA is a huge family of molecules, only some of them are described in literature affecting metabolic disorders. For example, miR-196a, miR-26, and miR-30 act as positive regulators and miR-155, miR-133, miR-27b, and miR-34 as negative regulators in complex diseases like obesity and diabetes (Karbiener and Scheidegger, 2014; Arias et al., 2015).

Transplantation of BAT

Newest way to improve quantity of BAT is transplantation. Some studies show very impressive results of this technique resulting in improved glucose tolerance and reduced body weight while some others show that transplanted BAT activates only BAT and muscle (Villarroya and Giralt, 2015). However, one question still remains, could this method be applied on humans too? Stanford et al. showed that some IRISIN (a cleavage product of Fndc5 gene) as one of the factors which can affect PRDM16 protein accumulation without full agonist and such compounds can have plausible therapeutic activity toward obesity and diabetes (Bostrom et al., 2012; Ohno et al., 2012; Stanford et al., 2015). Five proteins were identified as PGC1α target genes in muscle and likely to be secreted: IL-15, Fndc5, VEGFβ3, Lrg1, and TIMP4 (Bostrom et al., 2012; Stanford et al., 2015).

Exercise

As we can see from literature, one of the most beneficial things of exercise except browning is to improve the state of the whole body itself. Studies have shown that exercise training can increase the expression of most important metabolic proteins such as GLUT4 and PGC-1α (Fig. 2). Many of these metabolic adaptations to adipose tissue can occur independently of significant changes in weight loss. It is also showed that during exercise, SNS can be activated which promotes response from catecholamine. Therefore, adrenergic-receptor stimulation (β-AR stimulation) has chronic (mitochondrial biogenesis, recruitment of brown adipocytes in WAT) and acute (lipolysis) promotion of UCP1 (Sanchez-Delgado et al., 2015). Stanford et al. (2015) showed that exercise training results in profound changes to WAT, including increased expression of genes involved in mitochondrial biogenesis, increased mitochondrial activity, increased browning of scWAT, and an altered adipokine profile of WAT. Some studies showed that various myokines released from skeletal muscle during exercise can be responsible for browning such as meteorin-like 1, myostatin, and β-aminoisobutyric acid (BAIBA) as well as in humans (Zafrir, 2013; Stanford et al., 2015). On the other hand, first study on humans showed that both PGC1α and Fndc5 mRNA expression was increased in skeletal muscle in response to 12 weeks of training and the plasma concentration of IRISIN was reduced. There were little or no effects of long-term training on selected browning genes and also this group of scientist didn’t notice correlation between circulating IRISIN with UCP1 mRNA in subcutaneous adipose tissue. The role of IRISIN in the process of browning especially in humans is for serious debate and has been reviewed by Elsen et al. (Elsen et al., 2014; Norheim et al., 2014).

Musclin

Musclin—“exercise factor” or “exercise hormone” is a peptide produced by skeletal muscle as a response to exercise and it can be found in bloodstream. In a study done by Subbotina et al. (2015), it was showed that musclin as an exercise-responsive factor promotes skeletal muscle mitochondrial biogenesis and exercise endurance. Although the studies about musclin are scarce, the role of musclin seems to be very promising. Liu et al. had some interesting findings, where they reported that musclin reduced glucose uptake in rat skeletal muscle through mechanisms involving the inhibition of Akt/PKB. Moreover, they are proposing that PPARγ and liver X receptor α (LXRα) have a role in the reduction of glucose uptake in skeletal muscle exposed to musclin (Liu et al., 2008). Very similar findings were reported by Nishizawa et al. (2004). As we can conclude, possible role of mitochondria biogenesis and PPARγ in mechanism of musclin indicate that this peptide most probably has effects on the process of browning. In future, more studies should be done, especially with T2D patients in focus.

IRISIN

In last couple of years, special attention was given to IRISIN (a cleavage product of Fndc5 gene) as one of the factors which can help browning of fat. IRISIN is released into the bloodstream during exercise and promotes fat browning stimulated by UCP1 expression. High UCP1 expression caused by IRISIN is seen when it is injected in adenoviral particles to mice and finally this process leads to increase in energy expenditure and improvement in obesity and glucose homeostasis (Bostrom et al., 2012; Zafrir, 2013; Kürdiova et al., 2014; Rodriguez et al., 2015). However, a controversy exists concerning IRISIN origin, regulation and function in humans. Kürdiova et al. explored Fndc5 gene and IRISIN protein in two clinical studies: a cross-sectional study (effects of T2D in drug-naive men) and an intervention study (exercise effects in sedentary, overweight/obese individuals). They concluded the following: first, complex clinical studies combined with cell culture work
revealed that Fndc5/IRISIN was decreased in T2D in vivo, but not in muscle cells in vitro, indicating that diabetes-related factor(s) regulate Fndc5/IRISIN in vivo, second, several attributes of T2D, such as hyperglycaemia, triglyceridermia, visceral adiposity, and extramyocellular lipid deposition were negatively associated with adipose tissue Fndc5 mRNA and circulating IRISIN. Moreover, mimicking diabetic status in vitro by treating muscle cells with palmitate and glucose, lowered Fndc5 mRNA. However, IRISIN was positively linked to muscle mass, strength, and metabolism, pointing to common regulatory factors and/or the potential for IRISIN to modify muscle phenotype (Kurdiova et al., 2014). Myostatin and leptin have also been shown to negatively regulate IRISIN-induced fat browning (Rodriguez et al., 2015).

**GABA and BAIBA**

Very novel thing in literature is the effect of gamma amino butyric acid (GABA) on process of browning. GABA has a long history in commercial use as a food supplement according to its health functions. Recent studies show that GABA is a potential antioxidant and can regulate hyperglycaemia but unfortunately accurate mechanism is still unclear. Tian et al. (2011) have shown that it can be by regulating the redox status of muscle and plasma free amino acids (pFAAs). Moreover, according to these findings, Xie et al. did some experiments with different GABA supplements in three different doses on mice model on high fat diet. Their findings showed that treatment with GABA restored the redox status in muscle and HFD-induced pFAAs disorders to different extents, which may be responsible for the decrease of fasting blood glucose levels. However, the authors suggest to be careful with the dose of GABA, especially in preventing obesity (Xie et al., 2015). Long before that, Braun et al. (2004) showed that GABA by activation of GABAR receptors inhibits insulin secretion by suppression of exocytosis. GABARγ1 subunit can be novel target for treatment of many different modern lifestyle diseases, which has been shown by a study from Nakamura et al. In their experiments, they noticed that GABARγ1 subunit is constitutively expressed from adipocytes to primarily regulate leptin expression at the transcriptional level. This explains the possible functional role of GABA in adipocytes (Nakamura et al., 2011).

One of the newest things that are investigated in recent time are the effects of β-aminoisobutyric acid (BAIBA) on the process of browning and therefore its role in treatment of obesity and associated diseases. Roberts et al. (2014) first showed that BAIBA could be a new small molecular myokine. This group of scientists proved that BAIBA is regulated by PGC-1α and increases the expression of brown adipocyte-specific genes. According to these findings they tested new hypothesis whether BAIBA would induce a browning response in human pluripotent stem cells (PSCs) during their differentiation to mature white adipocytes. Their data indicated that BAIBA activates a browning gene program and increases the mitochondrial activity of human iPSCs differentiated into white adipocytes. The mechanism was unraveled by higher degree of UCP-1 staining in the PPAR-γ2 programmed white adipocytes treated with BAIBA when compared to untreated cells. Expression analysis of inguinal WAT using qPCR revealed significant increase in brown adipocyte-specific genes UCP-1 and CIDEA. Expression of PGC-1α and Cytochrome C were also increased following BAIBA treatment and demonstrated that BAIBA induces increased expression of brown/beige adipocyte-specific genes in vivo. Finally, we can say that BAIBA has been identified as a novel small molecular myokine representing the first in its class of non-adrenergic activators of the thermogenic program in WAT. The identification of BAIBA as a PGC-1α mediated and exercise triggered signal has significant implications not only for understanding of exercise and its protective role against the development of metabolic diseases, but also as potential therapeutics for T2D and the metabolic syndrome (Roberts et al., 2014).

One step closer to discovery of new facts about BAIBA and its role in T2D comes from Xiang Shi et al. in their experimental study. They showed that, oral administration of BAIBA attenuates hepatic endoplasmic reticulum (ER) stress, apoptosis, and glucose/lipid metabolic disturbance in mice with STZ/HFD-induced T2D. AMP-activated protein kinase (AMPK) signaling contributes to the role of BAIBA in attenuating ER stress. These findings regarding BAIBA provided new insights toward the development of therapeutic agents aimed at effectively reducing hepatic ER stress and glucose/lipid metabolic disturbance in T2D or other metabolic disorders (Shi et al., 2016). Previously, Jung et al. (2015) reported that BAIBA attenuates insulin resistance, suppresses inflammation, and induces fatty acid oxidation via the AMPK-PPARγ pathway in skeletal muscle. Although we have reviewed some of the most important factors for process of browning and show possible targets in developing a treatment for metabolic disorders with special reference to obesity and T2D, we should also highlight importance of browning and BAT for cardiovascular system especially because most common outcome of obesity and T2D are cardiovascular diseases.

**Is Browning of Fat Cardioprotective?**

There has been an increasing scientific interest in the BAT during the last few years since the discovery of BAT in adult humans. Although the thermogenic properties of BAT have been well established but their role in cardioprotection is unknown. The thermogenic property of BAT is attributed to high number of mitochondria and uncoupling of the electron transport chain due to high expression of uncoupling protein UCP1 (Cannon and Nedergraaf, 2004). The mice which are deficient in UCP1 are obese, cold sensitive, and have increased oxidative stress which suggests that UCP-1 has a systemic effect on the body (Feldmann et al., 2009). However, the link between brown fat, UCP-1, and cardiovascular function is unclear. In an attempt to find a link between brown fat and cardiac injury, Thoonen et al. (2015) used UCP1 knock out mice and induced cardiomyopathy using isoproterenol. Both WT and UCP1 knock out mice exhibited similar cardiac parameters like echocardiography, cardiac fibrosis, cardiac troponin, without isoproterenol treatment. However, when isoproterenol was administered, UCP1 knock out mice showed augmented myocardial injury, fibrosis, and decreased survival rates. Interestingly, when BAT from WT was transplanted to UCP1 knock out mice with isoproterenol treatment; it improved cardiac parameters and survival. This study suggested that BAT is cardioprotective and can minimize cardiac injury in ischemic condition. Another interesting study by Subhadra et al. demonstrated that surgical transplantation of BAT reversed type 1 diabetes in streptozotocin treated mice (Gunawardana and Piston, 2012). Transplantation of BAT resulted in normalized glucose tolerance and reduced tissue inflammation showing BAT to be beneficial for glucose metabolism.

Interestingly, the authors showed that BAT transplant increased levels of leptin and adiponectin. Secretion of these two endocrine factors suggested that BAT can behave as endocrine system and the endocrine factors secreted ('batokines') can be favorable against cardiovascular risk. Some of the 'batokines' to be listed which have a cardioprotective role are: (1) fibroblast growth factor 21 (FGF21) (Liu et al., 2013a; Planavila et al., 2013; Gimeno and Moller, 2014); (2) Interleukin 6 (IL-6) (Stanford et al., 2013; Fontes et al., 2015); (3) free fatty acids (Yore et al., 2014); and (4) nerve growth
factor (NGF) (Wei et al., 2015; Zheng et al., 2015). In view of the fact that BAT activation and batokines can contribute to cardioprotection (Fig. 3) and improve metabolic disorders, it can be proposed as a promising tool in clinical translation. Since BAT is present as a perivascular tissue, it has a profound effect on vascular tone and heart. Most vessels in the body are surrounded by perivascular adipose tissue (PVAT) except the cerebral vessels (Gao, 2007). The PVAT mostly share brown adipose tissue-like properties including high mitochondrial density and high expression of UCP1 (Chang et al., 2013). The epicardial adipose tissue (EAT) exhibits high UCP1 expression but its function still needs to be clear. The PVAT around the aorta is of significant interest, as it has been shown to promote vasorelaxation in aortic rings (Chang et al., 2013). The PVAT secretes a number of vasorelaxing factors such as adiponectin (Xu et al., 2010); gasotransmitters hydrogen sulfide (Wojcicka et al., 2011); nitric oxide (Gao et al., 2007), palmitic methyl ester (Lee et al., 2011). These vasorelaxing factors can modulate local blood pressure in the microvasculature (Houben et al., 2012). The UCP1 expression in the PVAT also contributes to blood pressure in humans (Li et al., 2015). PVAT is modestly anti-inflammatory and enhances endothelial-dependent and-independent vasorelaxation (Houben et al., 2012; Fitzgibbons and Czech, 2014). However, in metabolic diseases like obesity and diabetes, the role of PVAT may be altered from beneficial in lean and healthy to harmful in obese and diabetic (Lastra and Manrique, 2015). For example, in obesity PVAT secretes less adiponectin and more pro-inflammatory adipokines such as leptin, angiotensinogen, resistin, IL-6, TNF-α, and MCP-1 (Fitzgibbons and Czech, 2014). Overall, the BAT-like property of PVAT and its ability to vasorelaxation suggests that PVAT is an important factor in regulating vascular tone. Keeping in view the properties of BAT to protect from cardiac injury and vascular tone in the form of perivascular fat, it can be speculated that browning of white fat can be cardioprotective (Fig. 3). Hence, the factors that govern browning of fat have immense importance and can be targeted for future therapies.

Summary

Through this review it is clear that adrenergic system is not the only factor for the regulation of BAT activation but there are so many new therapeutic possibilities. Unfortunately, for many of these agents the underlying mechanisms are unclear and might turn out to be unsuitable for humans as much as it is for rodents. Although, we need to recognize that in this field 21st century leads in direction to define the organs with possible new endocrine role, but of course in the light of BAT. However, we say critically that many of those factors involved in the process of browning are discovered recently and their therapeutic activity is still a huge question mark. More studies should be conducted in future on humans with special emphasis on agents which can be used in therapeutic treatment for obesity and associated diseases especially because human body is still a mystery in so many ways.

Future Directions

Browning of fat can be a useful tool for treating metabolic disorders such as obesity and type 2 diabetes. With more and more research on factors that cause fat browning, it can lead to novel molecules with fewer side effects. High BAT prevalence indicates lean body mass, protection from obesity, healthy vascular tone, and less cardiovascular risk. Browning of epicardial fat can be a new target for cardioprotection which can provide energy in hypoxia. Since exercise leads to fat browning, stimulating GPCRs like GABA, PPARγ, BAIBA, and β2AR can be novel therapeutic strategies for fat browning. Use of adipoxines like FGF21, NGF, and interleukins is another aspect for fat browning strategies. Since BAT contains more number of mitochondria, we propose that factors which promote mitochondrial biogenesis can lead to fat browning as well as enhanced energy production. TFAM is a transcription factor that promotes mitochondrial biogenesis by enhancing mtDNA copy number and mitigates ROS production in mitochondria. We speculate that treatment of TFAM can promote fat browning as well as mitochondrial efficiency in VAT and lead to cardioprotection. Not to overstare in future, fat browning can be seen as a treatment for metabolic disorders as well as cardioprotection.

Literature Cited


Gil A, Olza J, Gil-Campos M, Gomez-Llorente C, Aguilera CM. 2011. Is adipose tissue a potential new endocrine role, but of course in the light of BAT. However, we say critically that many of those factors involved in the process of browning are discovered recently and their therapeutic activity is still a huge question mark. More studies should be conducted in future on humans with special emphasis on agents which can be used in therapeutic treatment for obesity and associated diseases especially because human body is still a mystery in so many ways.

Summary

Future Directions

Browning of fat can be a useful tool for treating metabolic disorders such as obesity and type 2 diabetes. With more and more research on factors that cause fat browning, it can lead to novel molecules with fewer side effects. High BAT prevalence indicates lean body mass, protection from obesity, healthy vascular tone, and less cardiovascular risk. Browning of epicardial fat can be a new target for cardioprotection which can provide energy in hypoxia. Since exercise leads to fat browning, stimulating GPCRs like GABA, PPARγ, BAIBA, and β2AR can be novel therapeutic strategies for fat browning. Use of adipoxines like FGF21, NGF, and interleukins is another aspect for fat browning strategies. Since BAT contains more number of mitochondria, we propose that factors which promote mitochondrial biogenesis can lead to fat browning as well as enhanced energy production. TFAM is a transcription factor that promotes mitochondrial biogenesis by enhancing mtDNA copy number and mitigates ROS production in mitochondria. We speculate that treatment of TFAM can promote fat browning as well as mitochondrial efficiency in VAT and lead to cardioprotection. Not to overstare in future, fat browning can be seen as a treatment for metabolic disorders as well as cardioprotection.
